Laryngeal Mask Airway (LMA) Insertion With Sevoflurane and Remifentanil

Gachon University Gil Medical Center

Status: Completed

Conditions: Laryngismus

Treatments: Drug: Remifentanil 1; Drug: Remifentanil 2; Drug: Control

Study type: Interventional

Funder types: Other

Identifiers

NCT01456299

AJIRB-MED-CT4-11-045 (Registry Identifier)

Details and patient eligibility

About

The purpose of this study was to determine the most suitable effect-site concentration of remifentanil for the LMA insertion during inhaled induction with 8% sevoflurane in adults.

Full description

For practical purposes, opioids with the ability to suppress upper airway reflexes have been used to facilitate insertion of the LMA during anaesthesia induction. To date, however, there have been no published reports addressing the use of remifentanil to facilitate LMA insertion during sevoflurane inhalation induction in adults. Therefore, the purpose of this study was to determine the most suitable effect-site concentration of remifentanil target-controlled infusion (TCI) for the LMA insertion during inhaled induction with 8% sevoflurane in adults.

Enrollment: 102 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, aged 18-60 with ASA physical status I or II, who were scheduled to minor elective surgery (< 1 h) were considered for the study

Exclusion criteria

• Exclusion criteria were allergies to the study drugs, a history of gastric reflux, a history of drug abuse, obesity (body mass index > 30 kg/m2) and suspected difficult airway

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

102 participants in 3 patient groups, including a placebo group

Control

Placebo Comparator group

Description:

The control group, which received an infusion of normal saline.

Treatment:

Drug: Control

Remifentanil 1

Active Comparator group

Description:

"Remifentanil 1": "The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml.

Treatment:

Drug: Remifentanil 1

Remifentanil 2

Active Comparator group

Description:

"Remifentanil 2": "The R2 group, which received a target effect-site remifentanil concentration of 2 ng/ml.

Treatment:

Drug: Remifentanil 2